1	Challenges	Challenge	B-NP	NNS	O	0	ROOT
2	in	in	B-PP	IN	O	1	NMOD
3	the	the	B-NP	DT	O	4	NMOD
4	control	control	I-NP	NN	O	2	PMOD
5	of	of	B-PP	IN	O	4	NMOD
6	gonorrhea	gonorrhea	B-NP	NN	O	5	PMOD
7	in	in	B-PP	IN	O	6	NMOD
8	South	South	B-NP	NNP	O	9	NMOD
9	America	America	I-NP	NNP	O	12	NMOD
10	and	and	O	CC	O	12	NMOD
11	the	the	B-NP	DT	O	12	NMOD
12	Caribbean	Caribbean	I-NP	NNP	O	7	PMOD
13	:	:	O	:	O	1	P
14	monitoring	monitor	B-VP	VBG	O	1	NMOD
15	the	the	B-NP	DT	O	16	NMOD
16	development	development	I-NP	NN	O	14	OBJ
17	of	of	B-PP	IN	O	16	NMOD
18	resistance	resistance	B-NP	NN	O	17	PMOD
19	to	to	B-PP	TO	O	18	NMOD
20	antibiotics	antibiotic	B-NP	NNS	O	19	PMOD
21	.	.	O	.	O	1	P

1	:	:	O	:	O	7	P
2	The	The	B-NP	DT	O	3	NMOD
3	objective	objective	I-NP	NN	O	7	SUB
4	of	of	B-PP	IN	O	3	NMOD
5	this	this	B-NP	DT	O	6	NMOD
6	study	study	I-NP	NN	O	4	PMOD
7	was	be	B-VP	VBD	O	0	ROOT
8	to	to	B-VP	TO	O	9	VMOD
9	ascertain	ascertain	I-VP	VB	O	7	PRD
10	the	the	B-NP	DT	O	12	NMOD
11	antimicrobial	antimicrobial	I-NP	JJ	O	12	NMOD
12	susceptibility	susceptibility	I-NP	NN	O	9	OBJ
13	of	of	B-PP	IN	O	12	NMOD
14	Neisseria	Neisseria	B-NP	NNP	O	16	NMOD
15	gonorrhoeae	gonorrhoeae	I-NP	NNP	O	16	NMOD
16	isolates	isolate	I-NP	NNS	O	13	PMOD
17	from	from	B-PP	IN	O	16	NMOD
18	6	6	B-NP	CD	O	24	NMOD
19	South	South	I-NP	JJ	O	24	NMOD
20	American	American	I-NP	JJ	O	24	NMOD
21	and	and	I-NP	CC	O	24	NMOD
22	13	13	I-NP	CD	O	24	NMOD
23	Caribbean	Caribbean	I-NP	JJ	O	24	NMOD
24	countries	country	I-NP	NNS	O	17	PMOD
25	participating	participate	B-VP	VBG	O	24	NMOD
26	in	in	B-PP	IN	O	25	VMOD
27	the	the	B-NP	DT	O	31	NMOD
28	Gonococcal	Gonococcal	I-NP	NNP	O	31	NMOD
29	Antimicrobial	Antimicrobial	I-NP	NNP	O	31	NMOD
30	Surveillance	Surveillance	I-NP	NNP	O	31	NMOD
31	Program	Program	I-NP	NNP	O	26	PMOD
32	(	(	O	(	O	34	DEP
33	GASP	GASP	B-NP	NN	B-protein	34	DEP
34	)	)	O	)	O	31	NMOD
35	from	from	B-PP	IN	O	31	NMOD
36	1990	1990	B-NP	CD	O	35	PMOD
37	to	to	B-PP	TO	O	31	NMOD
38	1999	1999	B-NP	CD	O	37	PMOD
39	.	.	O	.	O	7	P

1	:	:	O	:	O	7	P
2	A	A	B-NP	DT	O	4	NMOD
3	GASP	GASP	I-NP	NN	B-protein	4	NMOD
4	network	network	I-NP	NN	I-protein	7	SUB
5	of	of	B-PP	IN	O	4	NMOD
6	laboratories	laboratory	B-NP	NNS	O	5	PMOD
7	was	be	B-VP	VBD	O	0	ROOT
8	launched	launch	I-VP	VBN	O	7	VC
9	in	in	B-PP	IN	O	8	VMOD
10	the	the	B-NP	DT	O	11	NMOD
11	Americas	Americas	I-NP	NNP	O	14	NMOD
12	and	and	O	CC	O	14	NMOD
13	the	the	B-NP	DT	O	14	NMOD
14	Caribbean	Caribbean	I-NP	NNP	O	9	PMOD
15	during	during	B-PP	IN	O	8	VMOD
16	the	the	B-NP	DT	O	17	NMOD
17	1990s	1990s	I-NP	CD	O	15	PMOD
18	.	.	O	.	O	7	P

1	Standardized	Standardized	B-NP	JJ	O	2	NMOD
2	methods	method	I-NP	NNS	O	5	NMOD
3	and	and	O	CC	O	5	NMOD
4	interpretative	interpretative	B-NP	JJ	O	5	NMOD
5	criteria	criterion	I-NP	NNS	O	6	SUB
6	were	be	B-VP	VBD	O	23	VMOD
7	established	establish	I-VP	VBN	O	6	VC
8	for	for	B-PP	IN	O	7	VMOD
9	the	the	B-NP	DT	O	10	NMOD
10	isolation	isolation	I-NP	NN	O	8	PMOD
11	of	of	B-PP	IN	O	10	NMOD
12	N.	N.	B-NP	NNP	O	13	NMOD
13	gonorrhoeae	gonorrhoeae	I-NP	NNP	O	11	PMOD
14	,	,	O	,	O	23	P
15	strain	strain	B-NP	NN	O	16	NMOD
16	identification	identification	I-NP	NN	O	23	NMOD
17	,	,	O	,	O	23	P
18	and	and	O	CC	O	19	NMOD
19	determination	determination	B-NP	NN	O	23	NMOD
20	,	,	O	,	O	23	P
21	and	and	O	CC	O	23	NMOD
22	quality	quality	B-NP	NN	O	23	NMOD
23	control	control	I-NP	NN	O	0	ROOT
24	of	of	B-PP	IN	O	23	NMOD
25	antimicrobial	antimicrobial	B-NP	JJ	O	26	NMOD
26	susceptibility	susceptibility	I-NP	NN	O	24	PMOD
27	.	.	O	.	O	23	P

1	:	:	O	:	O	9	P
2	Two	Two	B-NP	CD	O	3	NMOD
3	countries	country	I-NP	NNS	O	9	SUB
4	(	(	O	(	O	8	DEP
5	Argentina	Argentina	B-NP	NNP	O	7	NMOD
6	and	and	I-NP	CC	O	7	NMOD
7	Uruguay	Uruguay	I-NP	NNP	O	8	DEP
8	)	)	O	)	O	3	NMOD
9	maintained	maintain	B-VP	VBD	O	0	ROOT
10	continuous	continuous	B-NP	JJ	O	11	NMOD
11	surveillance	surveillance	I-NP	NN	O	9	OBJ
12	during	during	B-PP	IN	O	9	VMOD
13	the	the	B-NP	DT	O	15	NMOD
14	study	study	I-NP	NN	O	15	NMOD
15	period	period	I-NP	NN	O	12	PMOD
16	.	.	O	.	O	9	P

1	Some	Some	B-NP	DT	O	2	NMOD
2	countries	country	I-NP	NNS	O	3	SUB
3	gathered	gather	B-VP	VBD	O	0	ROOT
4	data	datum	B-NP	NNS	O	8	NMOD
5	periodically	periodically	B-ADVP	RB	O	8	NMOD
6	and	and	O	CC	O	8	NMOD
7	several	several	B-NP	JJ	O	8	NMOD
8	others	other	I-NP	NNS	O	3	OBJ
9	were	be	B-VP	VBD	O	3	VMOD
10	unable	unable	B-ADJP	JJ	O	9	PRD
11	to	to	B-VP	TO	O	12	VMOD
12	initiate	initiate	I-VP	VB	O	10	AMOD
13	antimicrobial	antimicrobial	B-NP	JJ	O	14	NMOD
14	surveillance	surveillance	I-NP	NN	O	12	OBJ
15	as	as	B-PP	IN	O	12	VMOD
16	a	a	B-NP	DT	O	17	NMOD
17	result	result	I-NP	NN	O	15	PMOD
18	of	of	B-PP	IN	O	17	NMOD
19	lack	lack	B-NP	NN	O	18	PMOD
20	of	of	B-PP	IN	O	19	NMOD
21	resources	resource	B-NP	NNS	O	20	PMOD
22	.	.	O	.	O	3	P

1	The	The	B-NP	DT	O	2	NMOD
2	percentage	percentage	I-NP	NN	O	14	SUB
3	of	of	B-PP	IN	O	2	NMOD
4	penicillin-resistant	penicillin-resistant	B-NP	JJ	O	6	NMOD
5	N.	N.	I-NP	NNP	O	6	NMOD
6	gonorrhoeae	gonorrhoeae	I-NP	NNS	O	3	PMOD
7	isolated	isolate	B-VP	VBN	O	6	NMOD
8	in	in	B-PP	IN	O	7	VMOD
9	the	the	B-NP	DT	O	10	NMOD
10	region	region	I-NP	NN	O	8	PMOD
11	over	over	B-PP	IN	O	7	VMOD
12	the	the	B-NP	DT	O	13	NMOD
13	decade	decade	I-NP	NN	O	11	PMOD
14	varied	vary	B-VP	VBD	O	0	ROOT
15	considerably	considerably	B-ADVP	RB	O	14	VMOD
16	(	(	O	(	O	27	DEP
17	1.0-11.9	1.0-11.9	B-NP	CD	O	18	NMOD
18	%	%	I-NP	NN	O	19	SUB
19	carried	carry	B-VP	VBD	O	27	DEP
20	chromosomal	chromosomal	B-NP	JJ	O	21	NMOD
21	resistance	resistance	I-NP	NN	O	26	NMOD
22	and	and	O	CC	O	26	NMOD
23	17.9-38.8	17.9-38.8	B-NP	CD	O	24	NMOD
24	%	%	I-NP	NN	O	26	NMOD
25	produced	produce	B-NP	VBN	O	26	NMOD
26	beta-lactamase	beta-lactamase	I-NP	NN	O	19	OBJ
27	)	)	O	)	O	15	AMOD
28	with	with	B-PP	IN	O	15	PMOD
29	an	an	B-NP	DT	O	31	NMOD
30	overall	overall	I-NP	JJ	O	31	NMOD
31	trend	trend	I-NP	NN	O	28	PMOD
32	to	to	B-PP	TO	O	31	NMOD
33	declining	decline	B-NP	VBG	O	34	NMOD
34	numbers	number	I-NP	NNS	O	32	PMOD
35	of	of	B-PP	IN	O	34	NMOD
36	penicillin-resistant	penicillin-resistant	B-NP	JJ	O	37	NMOD
37	isolates	isolate	I-NP	NNS	O	35	PMOD
38	.	.	O	.	O	14	P

1	For	For	B-PP	IN	O	9	VMOD
2	tetracycline	tetracycline	B-NP	NN	O	1	PMOD
3	,	,	O	,	O	9	P
4	7.4	7.4	B-NP	CD	O	5	NMOD
5	%	%	I-NP	NN	O	9	SUB
6	to	to	B-PP	TO	O	5	NMOD
7	36.3	36.3	B-NP	CD	O	8	AMOD
8	%	%	I-NP	NN	O	6	PMOD
9	carried	carry	B-VP	VBD	O	0	ROOT
10	chromosomal	chromosomal	B-NP	JJ	O	11	NMOD
11	resistance	resistance	I-NP	NN	O	9	OBJ
12	,	,	O	,	O	9	P
13	whereas	whereas	O	IN	O	9	VMOD
14	12.0	12.0	B-NP	CD	O	15	NMOD
15	%	%	I-NP	NN	O	19	SUB
16	to	to	B-PP	TO	O	15	NMOD
17	27.4	27.4	B-NP	CD	O	18	AMOD
18	%	%	I-NP	NN	O	16	PMOD
19	carried	carry	B-VP	VBD	O	13	SBAR
20	plasmid-mediated	plasmid-mediated	B-NP	JJ	O	21	NMOD
21	resistance	resistance	I-NP	NN	O	19	OBJ
22	.	.	O	.	O	9	P

1	There	There	B-NP	EX	O	2	SUB
2	were	be	B-VP	VBD	O	0	ROOT
3	no	no	B-NP	DT	O	4	NMOD
4	reports	report	I-NP	NNS	O	2	PRD
5	of	of	B-PP	IN	O	4	NMOD
6	ciprofloxacin-resistant	ciprofloxacin-resistant	B-NP	JJ	O	7	NMOD
7	isolates	isolate	I-NP	NNS	O	5	PMOD
8	,	,	O	,	O	2	P
9	although	although	B-SBAR	IN	O	2	VMOD
10	N.	N.	B-NP	NNP	O	11	NMOD
11	gonorrhoeae	gonorrhoeae	I-NP	NNS	O	23	NMOD
12	with	with	B-PP	IN	O	11	NMOD
13	decreased	decrease	B-NP	VBN	O	14	NMOD
14	susceptibility	susceptibility	I-NP	NN	O	12	PMOD
15	to	to	B-PP	TO	O	14	NMOD
16	ciprofloxacin	ciprofloxacin	B-NP	NN	O	18	NMOD
17	and	and	I-NP	CC	O	18	NMOD
18	azithromycin	azithromycin	I-NP	NN	O	15	PMOD
19	as	as	B-CONJP	RB	O	23	NMOD
20	well	well	I-CONJP	RB	O	19	DEP
21	as	as	I-CONJP	IN	O	19	DEP
22	spectinomycin-resistant	spectinomycin-resistant	B-NP	JJ	O	23	NMOD
23	isolates	isolate	I-NP	NNS	O	24	SUB
24	were	be	B-VP	VBD	O	9	SBAR
25	identified	identify	I-VP	VBN	O	24	VC
26	in	in	B-PP	IN	O	25	VMOD
27	some	some	B-NP	DT	O	28	NMOD
28	countries	country	I-NP	NNS	O	26	PMOD
29	.	.	O	.	O	2	P

